SITRICK MICHAEL S 4

4 · APP Pharmaceuticals, Inc. · Filed Sep 15, 2008

Form 4

Period: 2008-09-10

Director

Transactions

Disposition to Issuer
Nonqualified Stock Option (Right to Purchase)
2008-09-10$10.28/sh−10,000$102,800→ 0 total
Exercise: $12.72Exp: 2017-12-19→ Common Stock (10,000 underlying)
Disposition to Issuer
Nonqualified Stock Option (Right to Purchase)
2008-09-10$10.27/sh−14,649$150,445→ 0 total
Exercise: $12.73Exp: 2016-08-01→ Common Stock (14,649 underlying)

Footnotes (2)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2008, among Fresenius SE, Fresenenius Kabi Pharmaceuticals Holding, Inc. (formerly Frensenius Kabi Pharmaceuticals Holding LLC), Fresenius Kabi Pharmaceuticals, LLC (?Merger Sub?) and APP Pharmaceuticals, Inc. (?APP?), whereby Merger Sub merged into APP with APP continuing as the surviving company and an indirect wholly owned subsidiary of Fresenius SE (the ?Merger?), this option, which was granted on August 1, 2006 and vested on the first anniversary of the grant date, was cancelled in exchange for a cash payment of $186,482, which represents the excess of $23.00 per share over the exercise price per share of this option.
[F2]Pursuant to the Merger, this option, which was granted on December 19, 2007 and vested on the first anniversary of the grant date, was cancelled in exchange for a cash payment of $127,200, which represents the excess of $23.00 per share over the exercise price per share of this option.

Documents

1 file